Conditions: Classical Hodgkin's Lymphoma
Keywords: Classical Hodgkin Lymphoma Classical Hodgkin's Lymphoma Hodgkin Lymphoma Hodgkin's Lymphoma Nodular sclerosing Mixed-cellularity Lymphocyte-rich Lymphocyte depleted HL Classical HL Refractory Hodgkin's Lymphoma Refractory Hodgkin Lymphoma Refractory HL
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 129
Healthy volunteers: no

Brief summary:
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.

Detailed description:

Arms:
arm 1: Participants received panobinostat 40 mg, capsules, orally, thrice every week (i.e. days 1, 3 and 5), in each cycle of 21 days until unacceptable toxicity, disease progression, start of new anti-cancer therapy or withdrawal of consent (up to approximately 48 months).

Interventions: intervention 1: Panobinostat
Intervention descriptions: intervention 1: Panobinostat hard gelatin capsules.

Protocol document: